FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
|Articles|April 7, 2021
COVID-19 Updates: US Vaccinations and Global Cases and Deaths as of April 7, 2021
Author(s)Sydney Jennings
Data from the Johns Hopkins COVID-19 interactive map and the CDC on COVID-19 cases, mortalities, vaccinations, and more.
Advertisement
How many people in the US have been vaccinated against COVID-19?
According to the US
• 33.1% of total US population have received at least 1 dose
• 19.4% of total US population are fully vaccinated
• 19.4% of total US population are fully vaccinated
The 5 states with the highest percentage of population fully vaccinated are:
1. New Mexico: 26.4%
2. Rhode Island: 25.3%
3. South Dakota 25.3%
4. Alaska: 24.9%
5. Maine: 24.3%
2. Rhode Island: 25.3%
3. South Dakota 25.3%
4. Alaska: 24.9%
5. Maine: 24.3%
How many cases of COVID-19 have been confirmed in the US?
According to the
• 30 876 041 confirmed cases
• 558 626 deaths
• 558 626 deaths
The 5 states with the highest total confirmed cases are:
1. California: 3 685 693
2. Texas: 2 812 046
3. Florida: 2 090 862
4. New York: 1 920 807
5. Illinois: 1 265 353
2. Texas: 2 812 046
3. Florida: 2 090 862
4. New York: 1 920 807
5. Illinois: 1 265 353
Deaths: California has the most deaths due to COVID-19 with 59 920 reported fatalities, followed by New York with 50 818, and Texas with 48 833.
How many cases of COVID-19 have been confirmed globally?
Globally, there have been 132 683 720 confirmed cases, 2 879 979 deaths, and 75 372 620 recoveries.
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.
September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
Advertisement
Advertisement
Trending on Patient Care Online
1
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
2
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
3
CagriSema Alters Food-Cue Responses, Reduces Organ Fat in New Analyses
4
Detecting Atrial Fibrillation in Primary Care: Warning Signs and Modifiable Risk Factors
5